Aligos Therapeutics, Inc.
NASDAQ:ALGS
11.44 (USD) • At close March 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 3.945 | 15.529 | 13.907 | 4.359 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 3.069 | 3.675 | 104.153 | 3.325 | 2.299 | 1.291 |
| Gross Profit
| 3.945 | 12.46 | 10.232 | -99.794 | -3.325 | -2.299 | -1.291 |
| Gross Profit Ratio
| 1 | 0.802 | 0.736 | -22.894 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 70.269 | 73.04 | 85.077 | 104.153 | 79.89 | 44.038 | 10.456 |
| General & Administrative Expenses
| 22.83 | 30.616 | 26.41 | 28.527 | 17.944 | 10.005 | 3.205 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 22.83 | 30.616 | 26.41 | 28.527 | 17.944 | 10.005 | 3.205 |
| Other Expenses
| 0 | 0 | 0 | 0 | -10.548 | 0.302 | -0.435 |
| Operating Expenses
| 93.099 | 103.656 | 111.487 | 132.68 | 97.834 | 54.043 | 13.661 |
| Operating Income
| -89.154 | -88.127 | -97.58 | -128.321 | -97.834 | -54.043 | -13.661 |
| Operating Income Ratio
| -22.599 | -5.675 | -7.017 | -29.438 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -41.726 | 1.243 | 1.64 | 0.132 | -10.548 | 1.864 | -0.272 |
| Income Before Tax
| -130.88 | -86.884 | -95.94 | -128.189 | -108.382 | -52.179 | -13.933 |
| Income Before Tax Ratio
| -33.176 | -5.595 | -6.899 | -29.408 | 0 | 0 | 0 |
| Income Tax Expense
| 0.331 | 0.795 | 0.106 | 0.143 | 0.161 | 0.085 | -0.272 |
| Net Income
| -131.211 | -87.679 | -96.046 | -128.332 | -108.543 | -52.264 | -13.933 |
| Net Income Ratio
| -33.26 | -5.646 | -6.906 | -29.441 | 0 | 0 | 0 |
| EPS
| -20.94 | -3.52 | -2.25 | -3.22 | -3.18 | -2.38 | -0.66 |
| EPS Diluted
| -20.94 | -3.52 | -2.25 | -3.22 | -3.18 | -2.38 | -0.66 |
| EBITDA
| -89.154 | -85.058 | -93.905 | -124.543 | -105.057 | -49.88 | -12.37 |
| EBITDA Ratio
| -22.599 | -5.477 | -7.017 | -29.438 | 0 | 0 | 0 |